Zhang Yuwei, Calado Rodrigo, Rao Mahadev, Hong Julie A, Meeker Alan K, Dumitriu Bogdan, Atay Scott, McCormick Peter J, Garfield Susan H, Wangsa Danny, Padilla-Nash Hesed M, Burkett Sandra, Zhang Mary, Kunst Tricia F, Peterson Nathan R, Xi Sichuan, Inchauste Suzanne, Altorki Nasser K, Casson Alan G, Beer David G, Harris Curtis C, Ried Thomas, Young Neal S, Schrump David S
Thoracic Surgery Section, Thoracic and GI Oncology Branch; National Cancer Institute, Bethesda, Maryland, United States of America.
National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States of America.
PLoS One. 2014 Jul 1;9(7):e101010. doi: 10.1371/journal.pone.0101010. eCollection 2014.
Although implicated in the pathogenesis of several chronic inflammatory disorders and hematologic malignancies, telomerase mutations have not been thoroughly characterized in human cancers. The present study was performed to examine the frequency and potential clinical relevance of telomerase mutations in esophageal carcinomas.
Sequencing techniques were used to evaluate mutational status of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC) in neoplastic and adjacent normal mucosa from 143 esophageal cancer (EsC) patients. MTS, flow cytometry, time lapse microscopy, and murine xenograft techniques were used to assess proliferation, apoptosis, chemotaxis, and tumorigenicity of EsC cells expressing either wtTERT or TERT variants. Immunoprecipitation, immunoblot, immunofluorescence, promoter-reporter and qRT-PCR techniques were used to evaluate interactions of TERT and several TERT variants with BRG-1 and β-catenin, and to assess expression of cytoskeletal proteins, and cell signaling. Fluorescence in-situ hybridization and spectral karyotyping techniques were used to examine telomere length and chromosomal stability.
Sequencing analysis revealed one deletion involving TERC (TERC del 341-360), and two non-synonymous TERT variants [A279T (2 homozygous, 9 heterozygous); A1062T (4 heterozygous)]. The minor allele frequency of the A279T variant was five-fold higher in EsC patients compared to healthy blood donors (p<0.01). Relative to wtTERT, A279T decreased telomere length, destabilized TERT-BRG-1-β-catenin complex, markedly depleted β-catenin, and down-regulated canonical Wnt signaling in cancer cells; these phenomena coincided with decreased proliferation, depletion of additional cytoskeletal proteins, impaired chemotaxis, increased chemosensitivity, and significantly decreased tumorigenicity of EsC cells. A279T expression significantly increased chromosomal aberrations in mouse embryonic fibroblasts (MEFs) following Zeocin™ exposure, as well as Li Fraumeni fibroblasts in the absence of pharmacologically-induced DNA damage.
A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal cancer cells. These findings warrant further analysis of A279T expression in esophageal cancers and premalignant esophageal lesions.
尽管端粒酶突变与多种慢性炎症性疾病和血液系统恶性肿瘤的发病机制有关,但在人类癌症中尚未得到充分表征。本研究旨在检测食管癌中端粒酶突变的频率及其潜在的临床相关性。
采用测序技术评估143例食管癌(EsC)患者肿瘤组织及癌旁正常黏膜中端粒酶逆转录酶(TERT)和端粒酶RNA组分(TERC)的突变状态。运用MTS、流式细胞术、延时显微镜和小鼠异种移植技术评估表达野生型TERT或TERT变体的EsC细胞的增殖、凋亡、趋化性和致瘤性。采用免疫沉淀、免疫印迹、免疫荧光、启动子报告基因和qRT-PCR技术评估TERT及多种TERT变体与BRG-1和β-连环蛋白的相互作用,并评估细胞骨架蛋白的表达和细胞信号传导。使用荧光原位杂交和光谱核型分析技术检测端粒长度和染色体稳定性。
测序分析发现1例涉及TERC的缺失(TERC del 341-360),以及2种非同义TERT变体[A279T(2例纯合,9例杂合);A1062T(4例杂合)]。与健康献血者相比,EsC患者中A279T变体的次要等位基因频率高5倍(p<0.01)。相对于野生型TERT,A279T缩短了端粒长度,破坏了TERT-BRG-1-β-连环蛋白复合物的稳定性,显著消耗了β-连环蛋白,并下调了癌细胞中的经典Wnt信号传导;这些现象与EsC细胞增殖减少、其他细胞骨架蛋白消耗、趋化性受损、化疗敏感性增加和致瘤性显著降低相一致。在Zeocin™处理后,A279T表达显著增加了小鼠胚胎成纤维细胞(MEF)中的染色体畸变,在无药物诱导DNA损伤的情况下,也增加了李-弗劳梅尼成纤维细胞中的染色体畸变。
A279T诱导食管癌细胞端粒功能障碍并抑制非经典端粒酶活性。这些发现值得进一步分析A279T在食管癌及癌前食管病变中的表达情况。